Pharmaceutical - Respiratory and Pulmonary, Johnson & Johnson

Filter

Popular Filters

EU approval for Janssen-Cilag's Dacogen and Novartis/Vectura's Seebri Breezhealer

01-10-2012

The European Commission on Friday approved the marketing authorization for Janssen-Cilag's (a unit of…

Astex PharmaceuticalsDacogenEuropeJanssen-CilagJohnson & JohnsonNovartisOncologyPharmaceuticalRegulationRespiratory and PulmonarySeebri BreezhalerVectura

Strong results for Bayer's Xarelto in treating pulmonary blood clots

27-03-2012

German drugs and crops sciences group Bayer (BAY: DE), and partner Janssen, part of US health care major…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalRegulationResearchRespiratory and PulmonaryXarelto

Caelyx and Ceplene manufacturing should be moved, says EMA

18-03-2012

The European Medicines Agency has recommended that the manufacturing processes for the anticancer medicines…

Boehringer IngelheimCaelyxCepleneEpiCeptJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationRespiratory and Pulmonary

Janssen drops deal with Orexo for OX-CLI/OX-ESI

01-02-2012

US health care major Johnson & Johnson INYSE: JNJ) subsidiary Janssen has decided to end research collaboration…

FinancialJanssenJohnson & JohnsonLicensingOrexo ABPharmaceuticalRespiratory and Pulmonary

Johnson & Johnson stops Doribax trial; reportedly agrees Risperdal settlement

09-01-2012

The US Food and Drug Administration says that a recent clinical trial with Doribax (doripenem) being…

DoribaxFinancialJanssenJohnson & JohnsonLegalNeurologicalNorth AmericaPharmaceuticalResearchRespiratory and PulmonaryRisperdal

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top